Dr. Hillel P. Cohen PhD is Executive Director of Scientific Affairs at Sandoz Inc., a division of Novartis, helping explain the principles of biosimilars and biosimilar policies to the healthcare community, patient advocacy groups, and other stakeholders. He has published and given presentations in the areas of biosimilar education, switching, interchangeability, totality-of-evidence, naming and safety. Dr. Cohen is a member of the Education and Communications committee of the Biosimilars Council, a division of the Association for Affordable Medicines He is also Co-Chair of the Science and Education Committee of the Biosimilars Forum. Dr. Cohen was one of the industry representatives in 2016 and again in 2021 in negotiations with FDA for renewal of the Biosimilars User Fee Act. He led the Sandoz efforts for presentation of the first US biosimilar, Zarxio® (filgrastim-sndz) to the US Oncology Advisory Committee. Prior to joining Sandoz he held multiple positions at Novartis Vaccines, including Head of Regulatory Affairs for North and Latin America and well as Head of Global Labeling. Dr. Cohen received a BA from New York University and a PhD in Biology from Dartmouth.